Altay Therapeutics Raises $37 Million in Series A Co — Led by Sound Bioventures, HealthCap

Altay Therapeutics closed a $37 million Series A financing co-led by Sound Bioventures and HealthCap. The biotechnology company develops small-molecule inhibitors of transcription factors. Proceeds will advance oral DUX4 inhibitor DX5057 through Phase 1 and Phase 2 proof-of-concept trials for facioscapulohumeral muscular dystrophy. A Phase 1 safety study is expected to begin in the first quarter of 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sound Bioventures Management AB published the original content used to generate this news brief on October 15, 2026, and is solely responsible for the information contained therein. (C)